Hematologic Cancers

A total of 80% of patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) achieved a complete response (CR) to axicabtagene ciloleucel (Yescarta), and those responses have proved durable, according to the interim results of the phase 2 ZUMA-5 study, said Caron A. Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting. Read More ›

According to long-term follow-up data presented at the ASCO 2020 virtual annual meeting, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has demonstrated ongoing durable remissions lasting up to 113 months for follicular lymphoma, 99 months for chronic lymphocytic leukemia (CLL), and 97 months for diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). Read More ›

  • Xospata Extends Overall Survival in Patients with FLT3 Mutation–Positive Relapsed or Refractory Acute Myeloid Leukemia
  • Published Results from KEYNOTE-048 Trial Show Extended Survival with Keytruda in Advanced Head and Neck Cancers
  • Discussing Costs of Genomic Testing with Patients
Read More ›

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied.

Read More ›

Educating Your Patients About Daratumumab
Leslie Lauersdorf insist that it's vital to inform your patients about what's involved in beginning daratumumab treatments, especially because of the lengthy chair time. Read More ›

How to Handle Survivorship Care for Multiple Myeloma
Tiffany Richards insists on the importance of survivorship care in patients with multiple myeloma and explains how to make sure patients stay as healthy as possible for as long as possible. Read More ›

How to Utilize New Mutliple Myeloma Drugs
Tiffany Richards is excited about all the new multiple myeloma treatments that are being introduced, but understands that the question of how to best utilize these drugs still remains to be answered. Read More ›

Preparing Your Patients for Side Effects
Tiffany Richards stresses the importance of educating patients about side effects and what to do when these side effects begin to present. Read More ›

Know Your Patients' Baselines
Tiffany Richards shares anecdotes that illustrate why it's important to really know your patients in order to effectively care for them. Read More ›

Meeting the Needs of the Patient
Tiffany Richards discusses the numerous, often unmet, needs of patients with multiple myeloma. Read More ›

Page 1 of 10


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: